TYRA (tyra.bio) Enterprise Value-to-Revenue Coefficient

Official company branding of Tyra Biosciences Inc (TYRA)

Tyra Biosciences, Inc. (TYRA) leverages the SNAP platform to create a closed-loop development cycle for FGFR inhibitors. The EV/Sales multiple reflects the business valuation dynamics, where the 0.00 metric indicates the value status relative to revenue. Diversified substance supplies across the US and Europe ensure stability, although sanction restrictions periodically hinder the international exchange of biomaterials and research.

tyra.bio (TYRA): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Tyra Biosciences (TYRA)

- price and consensus price forecast:
- business market valuation indicators:
- cash balance and cash flow data:
Fundamental company valuation:Tyra Biosciences, Inc. TYRA
Product sample of tyra.bio

This indicator serves as a stress-testing tool for asset valuation when constructing a conservative portfolio. The metric compares Enterprise Value (EV) to annual revenue, neutralizing the impact of debt load on the valuation. The current EV/Sales market multiple stands at 0.00, reflecting market expectations for capitalization. The trend of this indicator demonstrates the investment efficiency of Tyra Biosciences, Inc. (TYRA) in targeted therapy. Bio-waste disposal costs and ESG standards directly impact financial stability, which is reflected in the final valuation of the company.